Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 22, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001653821 | |
Entity Registrant Name | CEN BIOTECH INC | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-55557 | |
Entity Incorporation, State or Country Code | A6 | |
Entity Address, Address Line One | 300-3295 Quality Way | |
Entity Address, City or Town | Windsor | |
Entity Address, State or Province | ON | |
Entity Address, Postal Zip Code | N8T 3R9 | |
City Area Code | 519 | |
Local Phone Number | 419-4958 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 61,804,729 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash and cash equivalents | $ 66,046 | $ 193,198 |
Accounts receivable | 103,914 | 193,094 |
Prepaid expenses and other assets | 39,768 | 50,530 |
Income taxes refundable | 35,399 | 35,399 |
Loan receivable from Emergence Global Enterprises Inc. - related party | 0 | 0 |
Total current assets | 245,127 | 472,221 |
Other assets | ||
Operating lease right-of-use assets | 111,853 | 138,103 |
Other receivable | 5,338 | 0 |
Note receivable - CEN Biotech Ukraine LLC - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine LLC - related party | 1,299,328 | 1,299,328 |
Property and equipment, net | 77,399 | 97,403 |
Deferred income taxes | (2,720) | (2,720) |
Intangible assets, net | (4,972,976) | (5,072,031) |
Goodwill | 1,314,134 | 1,314,134 |
Total assets | 8,073,734 | 8,440,799 |
Current liabilities | ||
Accounts payable | 396,303 | 440,332 |
Accounts payable – related parties | 75,561 | 101,422 |
Loans payable | 1,688,793 | 1,688,793 |
Loans payable – related parties | 2,701,641 | 2,701,641 |
Convertible notes payable, net of unamortized discount | 713,330 | 643,330 |
Convertible notes payable, net of unamortized discount - related parties | 162,639 | 162,639 |
Accrued interest | 1,427,791 | 1,361,689 |
Accrued interest – related parties | 1,977,812 | 1,873,455 |
Operating lease liabilities | 115,709 | 103,908 |
Governmental assistance payable | 145,333 | 145,333 |
Accrued expenses | 322,158 | 638,073 |
Total current liabilities | 9,727,070 | 9,860,615 |
Operating lease liabilities, less current portion | 174,082 | 206,763 |
CEBA loan payable | 31,552 | 31,552 |
Total liabilities | 9,932,704 | 10,098,930 |
Commitments and contingencies (Notes 4, 11, 12, 18, 19, 24, and 25) | ||
Shareholders’ deficit | ||
Common stock; unlimited authorized shares; 61,804,729 and 55,957,743 issued and outstanding as of June 30, 2022, and December 31, 2021, respectively. No par value. | 0 | 0 |
Additional paid-in capital | 44,746,286 | 44,339,973 |
Accumulated deficit | (46,569,501) | (45,964,183) |
Accumulated other comprehensive loss | (35,755) | (33,921) |
Total shareholders’ deficit | (1,858,970) | (1,658,131) |
Total liabilities and shareholders’ deficit | $ 8,073,734 | $ 8,440,799 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Common stock, par value (in dollars per share) | $ 0 | $ 0 |
Common stock, authorized | Unlimited | Unlimited |
Common stock, shares issued (in shares) | 61,804,729 | 55,957,743 |
Common stock, shares outstanding (in shares) | 61,804,729 | 55,957,743 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Other Comprehensive (Loss) Income (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Revenue | $ 542,477 | $ 882,737 | ||
Operating expenses | ||||
Consulting fees | 148,839 | 897,000 | 195,850 | 897,000 |
Consulting fees – related parties | 46,800 | 0 | 78,000 | |
Stock-based compensation – employees | 14,925,572 | 0 | 15,001,322 | |
General and administrative | 693,611 | 394,205 | 1,126,736 | 632,095 |
Total operating expenses | 842,450 | 16,263,577 | 1,322,586 | 16,608,417 |
Loss from operations | (299,973) | (16,263,577) | (439,849) | (16,608,417) |
Other income (expense) | ||||
Interest expense | (31,227) | (162,975) | (66,102) | (293,603) |
Interest expense – related parties | (14,996) | (113,414) | (104,357) | (236,650) |
Interest income | 53 | 0 | 53 | 394 |
Change in fair value of patent acquisition liability | 1,078,000 | 1,078,000 | ||
Foreign exchange (loss) gain | (2,140) | (2,140) | (9,217) | (55,924) |
Other income (expense), net | (48,310) | 770,412 | (167,303) | 492,217 |
Net (loss) income | (348,283) | (15,493,165) | (607,152) | (16,116,200) |
Other comprehensive loss - Foreign currency translation | 0 | 0 | 0 | 0 |
Comprehensive (loss) income | $ (348,283) | $ (623,035) | $ (607,152) | $ 0 |
Net loss per share: | ||||
Basic and diluted (in dollars per share) | $ 0 | $ (0.06) | $ 0 | $ (0.11) |
Weighted average number of shares outstanding | ||||
Basic and diluted (in shares) | 61,341,187 | 27,207,044 | 61,341,187 | 27,091,577 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balances (in shares) at Dec. 31, 2020 | 27,557,363 | ||||
Balances at Dec. 31, 2020 | $ 0 | $ 17,068,810 | $ (27,060,527) | $ 0 | $ (9,991,717) |
Stock-based compensation | $ 0 | 75,750 | 0 | 0 | 75,750 |
Issuance of common stock – Interest shares (in shares) | 45,000 | ||||
Issuance of common stock – Interest shares | $ 0 | 62,100 | 0 | 0 | 62,100 |
Issuance of common stock – Settlement of accrued liability (in shares) | 8,369 | ||||
Issuance of common stock – Settlement of accrued liability | $ 0 | 13,390 | 0 | 0 | 13,390 |
Net loss | $ 0 | 0 | (623,035) | 0 | (623,035) |
Balances (in shares) at Mar. 31, 2021 | 27,610,732 | ||||
Balances at Mar. 31, 2021 | $ 0 | 17,220,050 | (27,683,562) | 0 | (10,463,512) |
Balances (in shares) at Dec. 31, 2020 | 27,557,363 | ||||
Balances at Dec. 31, 2020 | $ 0 | 17,068,810 | (27,060,527) | 0 | (9,991,717) |
Balances (in shares) at Dec. 31, 2021 | 55,957,743 | ||||
Balances at Dec. 31, 2021 | $ 0 | 44,339,973 | (45,964,183) | (33,921) | (1,658,131) |
Net loss | $ 0 | 0 | (257,035) | (1,834) | (258,869) |
Balances (in shares) at Mar. 31, 2022 | 55,957,743 | ||||
Balances at Mar. 31, 2022 | $ 0 | 44,339,973 | (46,221,218) | (35,755) | (1,917,000) |
Balances (in shares) at Dec. 31, 2021 | 55,957,743 | ||||
Balances at Dec. 31, 2021 | $ 0 | 44,339,973 | (45,964,183) | (33,921) | $ (1,658,131) |
Issuance of common stock – Interest shares (in shares) | 33,000 | ||||
Net loss | $ (607,152) | ||||
Balances (in shares) at Jun. 30, 2022 | 61,804,729 | ||||
Balances at Jun. 30, 2022 | $ 0 | 44,746,286 | (46,569,501) | (35,755) | (1,858,970) |
Balances (in shares) at Mar. 31, 2022 | 55,957,743 | ||||
Balances at Mar. 31, 2022 | $ 0 | 44,339,973 | (46,221,218) | (35,755) | (1,917,000) |
Issuance of common stock – Interest shares (in shares) | 33,000 | ||||
Issuance of common stock – Interest shares | $ 0 | 5,030 | 0 | 0 | 5,030 |
Net loss | $ 0 | 0 | (348,283) | 0 | $ (348,283) |
Issuance of common stock-Employment settlement agreement (in shares) | 5,350,444 | 5,350,444 | |||
Issuance of common stock-Employment settlement agreement | $ 0 | 401,283 | 0 | 0 | $ 401,283 |
Balances (in shares) at Jun. 30, 2022 | 61,804,729 | ||||
Balances at Jun. 30, 2022 | $ 0 | $ 44,746,286 | $ (46,569,501) | $ (35,755) | $ (1,858,970) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities | ||||||||
Net loss | $ (348,283) | $ (258,869) | $ (15,493,165) | $ (623,035) | $ (607,152) | $ (16,116,200) | ||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
Depreciation | 20,004 | 0 | ||||||
Amortization | 99,055 | 212,406 | ||||||
Amortization of debt discount | 75,755 | |||||||
Lease expense | 10,749 | |||||||
Stock-based compensation – employees | 14,925,572 | 0 | 15,001,322 | |||||
Stock-based compensation – non-employees | 897,000 | |||||||
Shares issued for interest | 5,030 | 103,350 | ||||||
Change in fair value of patent acquisition liability | (1,078,000) | (1,078,000) | ||||||
Foreign exchange loss (gain) | 55,924 | |||||||
Changes in operating assets and liabilities which provided (used) cash | ||||||||
Account Receivables | 89,180 | 0 | ||||||
Operating lease liabilities | (20,880) | 0 | ||||||
Prepaid expenses and other assets | 10,762 | 8,075 | ||||||
Other receivable | 20,912 | 89,370 | ||||||
Accounts payable | (44,029) | 59,459 | ||||||
Accounts payable – related parties | (25,861) | 0 | ||||||
Accrued interest – related and non-related parties | 170,459 | 325,327 | ||||||
Accrued expenses | (138,587) | 78,000 | ||||||
Net cash used in operating activities | (421,107) | (277,463) | ||||||
Cash flows used in investing activities | ||||||||
Advances to CEN Biotech Ukraine LLC | 0 | (120,000) | ||||||
Cash flows provided by financing activities | ||||||||
Repayment of loans payable - related parties | (50,000) | |||||||
Issuance of convertible notes | 70,000 | 408,395 | ||||||
Additional paid in capital | 406,313 | 0 | ||||||
Issuance of convertible notes – related parties | 0 | 48,000 | ||||||
Net cash provided by financing activities | 476,313 | 406,395 | ||||||
Net increase in cash and cash equivalents | 55,206 | 8,932 | ||||||
Cash and cash equivalents, beginning of period | $ 10,840 | $ 1,908 | 10,840 | 1,908 | $ 1,908 | |||
Cash and cash equivalents, end of period | $ 66,046 | $ 10,840 | 66,046 | 10,840 | $ 10,840 | $ 1,908 | ||
Supplemental cash flows disclosures | ||||||||
Cash paid for interest | 0 | 25,821 | ||||||
Non-cash transactions - investing and financing activities | ||||||||
Issuance of common stock - settlement of interest | 5,030 | 78,893 | ||||||
Issuance of common stock - settlement of accrued liability | 401,283 | 13,390 | ||||||
Convertible Debt [Member] | ||||||||
Cash flows provided by financing activities | ||||||||
Issuance of convertible notes | 70,000 | |||||||
Non-cash transactions - investing and financing activities | ||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 111,306 | $ 0 | ||||||
Conversion of Convertible Notes into Common Stock [Member] | ||||||||
Non-cash transactions - investing and financing activities | ||||||||
Issuance of common stock – upon conversion of convertible notes | 0 | 4,855,861 | ||||||
Conversion of Related Party Convertible Notes into Common stock [Member] | ||||||||
Non-cash transactions - investing and financing activities | ||||||||
Issuance of common stock – upon conversion of convertible notes | $ 0 | $ 68,000 |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | NOTE 1 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 X. not not December 31, 2021 There have been no 10 December 31, 2021. Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. three June 30, 2022, 2021, not Recent Developments In April 2021, no Recently Adopted Accounting Pronouncements No three June 30, 2022. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. |
Note 2 - Going Concern Uncertai
Note 2 - Going Concern Uncertainty / Management Plans | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 2 GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying condensed consolidated financial statements have been prepared in contemplating the continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $46,569,501 At June 30, 2022 no not not 5, 6, 7, 8. 19 no not The Company’s cash position may not Appointments of Officers and Directors On April 14, 2022, April 14, 2022. Appointment of Directors On April 18, 2022, April 18, 2022: ● Josef Tukacs ● George Dragicevic Dismissal of Independent Registered Accounting Firm On May 2, 2022, January 16, 2018. No December 31, 2021 December 31, 2020, not two May 2, 2022, ( no 304 1 not no 304 1 Engagement of New Independent Registered Accounting Firm On May 2, 2022, two December 31, 2021 2020, May 2, 2022, 304 1 304 1 |
Note 3 - Advances to CEN Biotec
Note 3 - Advances to CEN Biotech Ukraine and Acquisition of Clear Com Media | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | NOTE 3 ADVANCES TO CEN BIOTECH UKRAINE AND ACQUISITION OF CLEAR COM MEDIA At June 30, 2022 December 31, 2021, 11 Bahige (Bill) Chaaban, our former Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a former member of our Board of Directors, each directly own 25.5% of CEN Ukraine respectively. The remaining 49% of CEN Ukraine is owned by XN Pharma, which is an entity jointly owned by Bahige (Bill) Chaaban and Usamakh Saadikh. Bahige (Bill) Chaaban and Usamakh Saadikh do not not CEN acquired CCM on July 9, 2021. The merger was accounted for as a business combination using the acquisition method of accounting under the provisions of Accounting Standards Codification (ASC) 805, 805 805 The aggregate consideration for the acquisition of CCM was 4,000,000 shares of CEN common stock, which were issued pursuant to an exemption from registration under Section 4 2 1933, not July 9, 2021. September 30, 2021, December 31, 2021, September 30, 2021 Cash $ 259,470 Accounts receivable 210,536 Property and equipment 97,911 Other assets 244,540 Identifiable intangibles 456,855 Current financial liabilities (344,591 ) Other long-term liabilities (140,078 ) Total identifiable net assets 784,643 Goodwill 1,335,357 Net assets acquired $ 2,120,000 Identified intangible assets acquired include trade names, customer relationships, and product technology whose fair value of $456,855 is based on an appraisal report utilizing a combination of market, income, and multi-period excess earnings methods. These trade names and customer relationships are being amortized over useful lives ranging of 3 and 7 years, respectively, and the product technology is not not Amounts recognized as goodwill are expected to be fully deductible for Canadian income tax purposes. All goodwill has been included within the Digital segment. Costs related to the acquisition, which include legal, accounting, and valuation fees, in the amount of approximately $80,000 have been charged directly to operations and are included in general and administrative expenses in the 2021 Supplemental proforma financial information The unaudited financial information in the table below summarizes the combined results of operations of CEN and CCM on a pro forma basis, as though the companies had been combined as of the January 1, 2020. not January 1, 2020. 4,000,000 January 1, 2020 The pro forma financial information for the year ended December 31, 2021 2021, July 9, 2021, January 1, 2021 July 8, 2021. December 31, 2020 2020 2020. The following table summarizes the pro forma financial information (unaudited): Years Ended December 31, 2021 December 31, 2020 Revenue $ 1,305,985 $ 1,242,676 Operating expenses 20,437,863 3,720,279 Loss from operations (19,131,878 ) (2,477,603 ) Other income, net 57,949 16,950,653 (Loss) income before income taxes (19,073,929 14,473,050 Income tax expense (61,032 ) 32,892 Net (loss) income $ (19,012,897 $ 14,440,158 Net (Loss) Income Per Share Basic $ (0.43 ) $ 0.46 Diluted $ (0.43 ) $ 0.39 Weighted Average Number of Shares Outstanding Basic 44,488,649 31,264,072 Diluted 44,488,649 36,732,510 |
Note 4 - Intangible Assets
Note 4 - Intangible Assets | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | NOTE 4 INTANGIBLE ASSETS On September 12, 2016, August 31, 2016, Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 million upon commencement of public trading (b) The transfer of real properties located at 135 1517 1525 The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not In March 2018, one million September 30, 2018. October 4, 2018, December 15, 2018. April 3, 2019, December 31, 2019. March 16, 2020 December 31, 2021. March 2018 June 30, 2022 December 31, 2021, date using the current fair value of CEN’s common shares. On October 7, 2021, five October 7, 2021 four million The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no The intangible asset consists of the following at: 2022 2021 Estimated Life (years) Lighting patent $ 6,797,000 $ 6,797,000 16 Product technology 276,080 276,080 n/a Customer relationships 149,872 149,872 7 Capitalized software development costs 105,730 105,730 n/a Trade names 23,664 23,664 3 Total identifiable intangible assets 7,352,346 7,352,346 Less: Accumulated amortization 2,379,370 2,280,315 Net $ 4,972,976 $ 5,072,031 As of December 31, 2021 2020, 2031, 2032. July 9, 2021 2023, 2024, 2025 2026, 2028. not not |
Note 5 - Loans Payable
Note 5 - Loans Payable | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Short-Term Debt [Text Block] | NOTE 5 LOANS PAYABLE Loans payable consist of the following At June 30, 2022and December 31 2021: 2022 2021 Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713 7% $ 871,398 $ 871,398 Loans payable in default to multiple private investors bearing an interest at rates of up to 12% June 2018 May 2021 592,395 592,395 Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 April 16, 2022 100,000 100,000 Loan payable to Global Holdings International, LLC, which bears interest at 15% June 30, 2016 75,000 75,000 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 July 16, 2021 50,000 50,000 Mortgage payable to ARG & Pals, Inc., for the original amount of CAD 385,000. The mortgage bears interest at 22% per annum, is unsecured, and matured on September 21, 2021. This was assumed on October 7, 2021 by the Sellers as described in Note 8. - - Total loans payable (all current) $ 1,688,793 $ 1,688,793 During 2020, June 30, 2016 no November 2020. 2002, 2002, 24, 2 June 30, 2016, 2 405 20 40 1 During both 2021 2020, December 31, 2021, one not 2021 2020, During 2021, no The Canada Emergency Business Account (“CEBA”) loan payable of $31,552 (CAD 40,000) as of December 31, 2021, December 2022 not December 31, 2023, December 2025. The Canadian government enacted the Canada Emergency Wage Subsidy (“CEWS”) and Canada Emergency Rent Subsidy (“CERS”) in 2020 19 2021 December 31, 2021 |
Note 6 - Loans Payable- Related
Note 6 - Loans Payable- Related Party | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Loans Payable to Related Party [Text Block] | NOTE 6 LOANS PAYABLE- RELATED PARTY Loans payable - related party consists of the following At June 30, 2022 December 31 2021: 2022 2021 Loan payable in default due to the spouse of Bill Chaaban, former CEO of CEN, which bears an interest at 12% August 17, 2020 $ 1,388,122 $ 1,388,122 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the former CEO of CEN, bearing interest at 8% October 2, 2019 300,000 300,000 Loans payable in default to the spouse of Bill Chaaban, former CEO of CEN, for the original amounts of CAD 48,630 198,660 10% December 31, 2018 237,019 237,019 Loan payable to the spouse of Joseph Byrne, a 5% 4,000 April 16, 2022 100,000 100,000 Loan payable to Alex Tarrabain, former CFO and Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 April 16, 2022 75,000 75,000 Loan payable to Joseph Byrne, a 5% 2,000 - - Total loans payable – related party (all current) $ 2,701,641 $ 2,701,641 Attributable related party accrued interest was $671,665 and $568,969 as of December 31, 2021 2020, 2021 2020, During both June 30 2022 December 31, 2021, June 30, 2022 2020, |
Note 7 - Convertible Notes
Note 7 - Convertible Notes | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Long-Term Debt [Text Block] | NOTE 7 CONVERTIBLE NOTES Convertible notes payable consists of the following At June 30, 2022 December 31 2021: 2022 2021 Convertible notes payable in default to multiple private investors, including certain notes in default, bearing interest at 5% 363,767 May 2018 October 2021 $ 576,472 $ 576,472 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5% 550,965 June 2022 December 2022 145,000 145,000 Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7% 335,833 - - Convertible note payable for the original amount of USD 70,000 8% 65% 35% 70,000 - Total convertible notes payable 791,472 721,472 Less unamortized debt discount 78,142 78,142 Total convertible notes payable, net of unamortized debt discount 713,330 643,330 Less current portion 713,330 643,330 Convertible notes payable, less current portion $ - $ - The Company issues convertible notes as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued during 2021 2021 2020. may During the year 2022, During 2021, no 2021. As of August 14, 2022, no Q1 2022 Q2 2022 |
Note 8 - Convertible Notes - Re
Note 8 - Convertible Notes - Related Party | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Long-term Convertible Notes Related Party [Text Block] | NOTE 8 CONVERTIBLE NOTES RELATED PARTY Convertible notes – related party consists of the following At June 30, 2022 December 31 2021: 2022 2021 Convertible notes, in default, due to Joseph Byrne, former President, CEO, and Member of the board of CEN, bearing interest at 12% 76,123 August 17, 2020 $ 121,796 $ 121,796 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5% 94,488 May 24, 2022 48,000 48,000 Total convertible notes payable – related parties 169,796 169,796 Less unamortized debt discount 7,157 7,157 Total convertible notes payable - related parties (all current) $ 162,639 $ 162,639 Attributable related party accrued interest was $1,977,812 and $1,201,790 as of June 30, 2022, December 31, 2021, June 2022 December 2021, The Company issues convertible notes to related parties as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued to related parties during 2021 2021 2020. may During 2021, As of August 14, 2022, |
Note 9 - Income Taxes
Note 9 - Income Taxes | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 9 INCOME TAXES The Company has elected to file separate Canadian income tax returns for CEN (growth) and for CCM (digital). Growth: As of June 30, 2022, may 20 2034. may not not December 31: 2022 2021 Deferred tax asset - net operating losses $ 8,300,000 $ 3,400,000 Deferred tax asset valuation allowance (8,300,000 ) (3,400,000 ) Net deferred tax asset $ - $ - The change in the valuation allowance amounted to $4,900,000 and $3,400,000 for the years ended December 31, 2021 2020, Digital: The tax benefit for CCM income taxes consists of the following components: December 31, 2021 Current $ (33,621 ) Deferred (2,735 ) Net income tax benefit $ (36,356 ) The net deferred income tax asset presented in the consolidated balance sheets is comprised of the following at: December 31, 2021 Deferred tax assets SR&ED credits $ 39,464 Deferred tax liabilities Property and equipment (11,357 ) Intangible assets, including goodwill (25,387 ) Total deferred tax liabilities (36,744 ) Net deferred tax asset $ 2,720 A reconciliation of the income tax benefit and the amount computed by applying the statutory Canadian federal income tax rate to CEN’s and CCM’s income before income tax benefit for the year ended December 31 2021 2020 Growth Digital Total Growth Digital Total Income tax (benefit) expense at statutory rate of 26.5% $ (5,020,280 ) $ 1,177 $ (5,019,103 ) $ 3,776,156 $ - $ 3,776,156 Valuation allowance 5,020,280 - 5,020,280 (3,776,156 ) - (3,776,156 ) SR&ED credits - (19,198 ) (19,198 ) - - - Other - (18,335 ) (18,335 ) - - - Income tax benefit $ - $ (36,356 ) $ (36,356 ) $ - $ - $ - Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of December 31, 2021, no no no 2018. |
Note 10 - Shareholders' Deficit
Note 10 - Shareholders' Deficit / Stock Activity | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 10 SHAREHOLDERS DEFICIT / STOCK ACTIVITY The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value. During the quarter end, 5,350,444 common shares was issued to former employee as settlement of employment related liability. During the year 2022, As of December 31, 2021, one 9, not As of December 31, 2021, |
Note 11 - Related Party Transac
Note 11 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 11 RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 6 8. A loan totaling $17,901 was made to Emergence Global as of December 31, 2020. July 2017 November 13, 2019. May 6, 202. There are advances of $1,299,328 and $1,179,328 to CEN Ukraine as of December 31, 2021 2020, 7. December 3, 2017, December 14, 2017, not April 14, 2022, not not During the years ended December 31, 2021 2020, December 31, 2021 2020, During the year ended December 31, 2021, During 2017, 10 2017 2026. No December 31, 2021. 25 As of December 31, 2021 2020, During 2021, December 31, 2021, As of December 31, 2021, The Company currently leases certain facilities and equipment under noncancelable operating lease agreements that expire at various dates through 2024. The Company also leased office space in Windsor, Ontario from RN Holdings Ltd. Under the lease agreement effective October 1, 2017, September 2022, August 1, 2020, no August 1, 2020. August 1, 2020 April 14, 2022, not December 31, 2021 December 31, 2021 2020 2021 2020, The operating lease liability as of December 31, 2021 2020 2021 2020, Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased a property at 20 January 2017 4,000 five third October 2019. August 1, 2020, August 1, 2020 2020, The following is a schedule of future annual minimum rental payments required under operating leases with initial or remaining noncancelable lease terms in excess of one 12 December 31: Amount 2022 $ 119,543 2023 90,325 2024 61,897 2025 32,088 2026 32,088 Thereafter 24,066 Total lease payments $ 360,007 Less imputed interest 49,336 Present value of lease liability $ 310,671 |
Note 12 - Stock Based Compensat
Note 12 - Stock Based Compensation | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | NOTE 12 STOCK BASED COMPENSATION Adoption of Equity Compensation Plan On November 29, 2017, 2017 On April 2, 2021, 2021 2021 2021 Equity Compensation Grants On November 30, 2017, one 36 November 2020. 36 November 2020. On April 17, 2020, three On August 27, 2020 September 25, 2020, two On April 2, 2021, 12 On July 13, 2021, two Employment Agreements On November 30, 2017, four ● Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 and a grant of 8,750,000 shares of restricted stock of the Company, of which 7,400,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ● Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 and a grant of 1,250,000 shares of restricted stock of the Company, of which 325,000 vested immediately and the remaining vesting ratably each month over the next 36 November 2020. November 13, 2019, April 2, 2020, not ● Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 and a grant of 4,500,000 shares of restricted stock of the Company, of which 4,140,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ● Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 36 November 2020. On May 16, 2019, one 36 May 2022. On December 6, 2021, 36 December 2024. On April 2, 2021, On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021 June 25, 2021, 2021 On April 14, 2022, April 14, 2022. April 14, 2022. April 14, 2022. April 14, 2022. April 14, 2022. April 15, 2022. On April 19, 2022, June 2018. The foregoing resignations shall be referred to together herein as the “Resignations”. Subsequent to the effectiveness of the above Resignations, the above name persons no not Settlement Agreements with Departing Officers and Directors As reported by the Company on its Current Report on Form 8 April 19, 2022, April 14, 2022, April 14, 2022. April 14, 2022. April 14, 2022. April 14, 2022. April 14, 2022. April 15, 2022. no On April 19, 2022, November 30, 2017, April 14, 2022. may On April 19, 2022, May 21, 2019, April 14, 2022. may On April 19, 2022, December 6, 2021, April 14, 2022. On April 19, 2022, April 2, 2021, April 14, 2022. On April 19, 2022, November 30, 2017, April 15, 2022. Restricted Stock Awards Restricted stock awards relate to common shares that are subject to applicable securities laws and regulations as set forth in the RSAs and other equity compensation grants. The total grant-date fair value of the restricted shares granted through employment agreements and equity compensation grants was $29,885,063 and $13,013,241 as of December 31, 2021 2020, 2021 2020, April 5, 2021 April 5, 2021, With the exception of immediately vesting portions of awards, shares typically vest pro-rata over the requisite service period, which is generally three During 2021 2020, 2021 2020, Compensation expense, broken out by allocation, recognized in connection with the restricted stock awards was as follows for the years ended December 31: 2022 2021 Stock Based Compensation $ - $ 15,390,822 Professional fees - 1,172,000 Total $ - $ 16,562,822 Non-vested restricted stock award activity for the years ended June 30, 2022 2021 Number of Weighted- Grant Date Fair Value Weighted- Non-vested at January 31, 2021 425,000 $ 1.01 1.50 Granted 15,059,291 1.12 - Vested (13,559,291 ) 1.22 - Forfeited - - - Non-vested at December 31, 2021 1,925,000 $ 0.38 2.84 The fair value of the restricted stock grants was based on the valuation of a third April 5, 2021. April 5, 2021, December 31, 2021, December 2024. |
Note 13 - Net Loss Per Share
Note 13 - Net Loss Per Share | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | NOTE 13 NET LOSS PER SHARE During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of December 31, 2021. 2020, 8, June 30, December 2021 2021 2020 Convertible debt 1,085,343 - Tesla agreement - 1,000,000 The following table shows the computation of basic and diluted earnings per share for 2021: Income Shares Per-Share (Numerator) (Denominator) Amount Basic EPS Income available to common stockholders $ 607,152 61,341,187 $ 0.00 Effect of Dilutive Securities Convertible debt - - - Diluted EPS Income available to common stockholders with assumed conversions $ 607,152 61,341,187 $ 0.00 |
Note 14 - Contingency
Note 14 - Contingency | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 14 CONTINGENCY In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 10 May 4, 2016 5 not |
Note 15 - Fair Value Disclosure
Note 15 - Fair Value Disclosures | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 15 FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2022: Cash and cash equivalents $ 66,046 $ - $ 66,046 $ - $ 66,046 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,688,793 $ - $ - $ 1,688,793 $ 1,688,793 Loans payable – related parties $ 2,701,641 $ - $ - $ - $ - Convertible notes payable $ 713,330 $ - $ - $ 713,330 $ 713,330 Convertible notes payable – related parties $ 162,639 $ - $ - $ - $ - CEBA loan payable $ 47,400 $ - $ - $ 47,400 $ 47,400 Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 193,198 $ - $ 193,198 $ - $ 193,198 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,688,793 $ - $ - $ 1,688,793 $ 1,688,793 Loans payable – related parties $ 2,701,641 $ - $ - $ - $ - Convertible notes payable $ 643,330 $ - $ - $ 1,890,736 $ 1,890,736 Convertible notes payable – related parties $ 162,639 $ - $ - $ - $ - CEBA loan payable $ 31,552 $ - $ - $ 31,552 $ 31,552 The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3 rd April 5, 2021. April 5, 2021, 3 1 2021. October 7, 2021, 8. |
Note 16 - Subsequent Events
Note 16 - Subsequent Events | 6 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 16 SUBSEQUENT EVENTS On May 24, 2022, Company Agreement Buyer No. 8,723,425, May 13, 2014, Patent seven four hundred forty thousand Shares Payment not On July 19, 2022, no |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. three June 30, 2022, 2021, not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements No three June 30, 2022. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. |
Note 3 - Advances to CEN Biot_2
Note 3 - Advances to CEN Biotech Ukraine and Acquisition of Clear Com Media (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | Cash $ 259,470 Accounts receivable 210,536 Property and equipment 97,911 Other assets 244,540 Identifiable intangibles 456,855 Current financial liabilities (344,591 ) Other long-term liabilities (140,078 ) Total identifiable net assets 784,643 Goodwill 1,335,357 Net assets acquired $ 2,120,000 |
Business Acquisition, Pro Forma Information [Table Text Block] | Years Ended December 31, 2021 December 31, 2020 Revenue $ 1,305,985 $ 1,242,676 Operating expenses 20,437,863 3,720,279 Loss from operations (19,131,878 ) (2,477,603 ) Other income, net 57,949 16,950,653 (Loss) income before income taxes (19,073,929 14,473,050 Income tax expense (61,032 ) 32,892 Net (loss) income $ (19,012,897 $ 14,440,158 Net (Loss) Income Per Share Basic $ (0.43 ) $ 0.46 Diluted $ (0.43 ) $ 0.39 Weighted Average Number of Shares Outstanding Basic 44,488,649 31,264,072 Diluted 44,488,649 36,732,510 |
Note 4 - Intangible Assets (Tab
Note 4 - Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | 2022 2021 Estimated Life (years) Lighting patent $ 6,797,000 $ 6,797,000 16 Product technology 276,080 276,080 n/a Customer relationships 149,872 149,872 7 Capitalized software development costs 105,730 105,730 n/a Trade names 23,664 23,664 3 Total identifiable intangible assets 7,352,346 7,352,346 Less: Accumulated amortization 2,379,370 2,280,315 Net $ 4,972,976 $ 5,072,031 |
Note 5 - Loans Payable (Tables)
Note 5 - Loans Payable (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Short-Term Debt [Table Text Block] | 2022 2021 Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713 7% $ 871,398 $ 871,398 Loans payable in default to multiple private investors bearing an interest at rates of up to 12% June 2018 May 2021 592,395 592,395 Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 April 16, 2022 100,000 100,000 Loan payable to Global Holdings International, LLC, which bears interest at 15% June 30, 2016 75,000 75,000 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 July 16, 2021 50,000 50,000 Mortgage payable to ARG & Pals, Inc., for the original amount of CAD 385,000. The mortgage bears interest at 22% per annum, is unsecured, and matured on September 21, 2021. This was assumed on October 7, 2021 by the Sellers as described in Note 8. - - Total loans payable (all current) $ 1,688,793 $ 1,688,793 |
Note 6 - Loans Payable- Relat_2
Note 6 - Loans Payable- Related Party (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Loans Payable to Related Party [Table Text Block] | 2022 2021 Loan payable in default due to the spouse of Bill Chaaban, former CEO of CEN, which bears an interest at 12% August 17, 2020 $ 1,388,122 $ 1,388,122 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the former CEO of CEN, bearing interest at 8% October 2, 2019 300,000 300,000 Loans payable in default to the spouse of Bill Chaaban, former CEO of CEN, for the original amounts of CAD 48,630 198,660 10% December 31, 2018 237,019 237,019 Loan payable to the spouse of Joseph Byrne, a 5% 4,000 April 16, 2022 100,000 100,000 Loan payable to Alex Tarrabain, former CFO and Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 April 16, 2022 75,000 75,000 Loan payable to Joseph Byrne, a 5% 2,000 - - Total loans payable – related party (all current) $ 2,701,641 $ 2,701,641 |
Note 7 - Convertible Notes (Tab
Note 7 - Convertible Notes (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Long-Term Debt Instruments [Table Text Block] | 2022 2021 Convertible notes payable in default to multiple private investors, including certain notes in default, bearing interest at 5% 363,767 May 2018 October 2021 $ 576,472 $ 576,472 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5% 550,965 June 2022 December 2022 145,000 145,000 Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7% 335,833 - - Convertible note payable for the original amount of USD 70,000 8% 65% 35% 70,000 - Total convertible notes payable 791,472 721,472 Less unamortized debt discount 78,142 78,142 Total convertible notes payable, net of unamortized debt discount 713,330 643,330 Less current portion 713,330 643,330 Convertible notes payable, less current portion $ - $ - |
Note 8 - Convertible Notes - _2
Note 8 - Convertible Notes - Related Party (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Convertible Notes Payable to Related Party [Table Text Block] | 2022 2021 Convertible notes, in default, due to Joseph Byrne, former President, CEO, and Member of the board of CEN, bearing interest at 12% 76,123 August 17, 2020 $ 121,796 $ 121,796 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5% 94,488 May 24, 2022 48,000 48,000 Total convertible notes payable – related parties 169,796 169,796 Less unamortized debt discount 7,157 7,157 Total convertible notes payable - related parties (all current) $ 162,639 $ 162,639 |
Note 9 - Income Taxes (Tables)
Note 9 - Income Taxes (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2022 2021 Deferred tax asset - net operating losses $ 8,300,000 $ 3,400,000 Deferred tax asset valuation allowance (8,300,000 ) (3,400,000 ) Net deferred tax asset $ - $ - December 31, 2021 Deferred tax assets SR&ED credits $ 39,464 Deferred tax liabilities Property and equipment (11,357 ) Intangible assets, including goodwill (25,387 ) Total deferred tax liabilities (36,744 ) Net deferred tax asset $ 2,720 |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | December 31, 2021 Current $ (33,621 ) Deferred (2,735 ) Net income tax benefit $ (36,356 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2021 2020 Growth Digital Total Growth Digital Total Income tax (benefit) expense at statutory rate of 26.5% $ (5,020,280 ) $ 1,177 $ (5,019,103 ) $ 3,776,156 $ - $ 3,776,156 Valuation allowance 5,020,280 - 5,020,280 (3,776,156 ) - (3,776,156 ) SR&ED credits - (19,198 ) (19,198 ) - - - Other - (18,335 ) (18,335 ) - - - Income tax benefit $ - $ (36,356 ) $ (36,356 ) $ - $ - $ - |
Note 11 - Related Party Trans_2
Note 11 - Related Party Transactions (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Amount 2022 $ 119,543 2023 90,325 2024 61,897 2025 32,088 2026 32,088 Thereafter 24,066 Total lease payments $ 360,007 Less imputed interest 49,336 Present value of lease liability $ 310,671 |
Note 12 - Stock Based Compens_2
Note 12 - Stock Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | 2022 2021 Stock Based Compensation $ - $ 15,390,822 Professional fees - 1,172,000 Total $ - $ 16,562,822 |
Nonvested Restricted Stock Shares Activity [Table Text Block] | Number of Weighted- Grant Date Fair Value Weighted- Non-vested at January 31, 2021 425,000 $ 1.01 1.50 Granted 15,059,291 1.12 - Vested (13,559,291 ) 1.22 - Forfeited - - - Non-vested at December 31, 2021 1,925,000 $ 0.38 2.84 |
Note 13 - Net Loss Per Share (T
Note 13 - Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | 2021 2020 Convertible debt 1,085,343 - Tesla agreement - 1,000,000 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Income Shares Per-Share (Numerator) (Denominator) Amount Basic EPS Income available to common stockholders $ 607,152 61,341,187 $ 0.00 Effect of Dilutive Securities Convertible debt - - - Diluted EPS Income available to common stockholders with assumed conversions $ 607,152 61,341,187 $ 0.00 |
Note 15 - Fair Value Disclosu_2
Note 15 - Fair Value Disclosures (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Fair Value, by Balance Sheet Grouping [Table Text Block] | Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2022: Cash and cash equivalents $ 66,046 $ - $ 66,046 $ - $ 66,046 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,688,793 $ - $ - $ 1,688,793 $ 1,688,793 Loans payable – related parties $ 2,701,641 $ - $ - $ - $ - Convertible notes payable $ 713,330 $ - $ - $ 713,330 $ 713,330 Convertible notes payable – related parties $ 162,639 $ - $ - $ - $ - CEBA loan payable $ 47,400 $ - $ - $ 47,400 $ 47,400 Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 193,198 $ - $ 193,198 $ - $ 193,198 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 1,688,793 $ - $ - $ 1,688,793 $ 1,688,793 Loans payable – related parties $ 2,701,641 $ - $ - $ - $ - Convertible notes payable $ 643,330 $ - $ - $ 1,890,736 $ 1,890,736 Convertible notes payable – related parties $ 162,639 $ - $ - $ - $ - CEBA loan payable $ 31,552 $ - $ - $ 31,552 $ 31,552 |
Note 2 - Going Concern Uncert_2
Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Retained Earnings (Accumulated Deficit), Total | $ (46,569,501) | $ (45,964,183) |
Note 3 - Advances to CEN Biot_3
Note 3 - Advances to CEN Biotech Ukraine and Acquisition of Clear Com Media (Details Textual) - USD ($) | 6 Months Ended | 12 Months Ended | ||||||
Jul. 09, 2021 | Jul. 09, 2021 | Dec. 31, 2021 | Jun. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 02, 2017 | |
Finite-Lived Intangible Assets, Accumulated Amortization | $ 2,379,370 | $ 2,280,315 | ||||||
Clear Com Media, Inc [Member] | ||||||||
Stock Issued During Period, Shares, Acquisitions (in shares) | 4,000,000 | |||||||
Stock Issued During Period, Value, Acquisitions | $ 2,120,000 | |||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable | $ 8,000 | |||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles | (168,000) | |||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities | 23,000 | |||||||
Goodwill, Purchase Accounting Adjustments | 184,000 | |||||||
Finite-lived Intangible Assets Acquired | $ 456,855 | |||||||
Clear Com Media, Inc [Member] | General and Administrative Expense [Member] | ||||||||
Business Combination, Acquisition Related Costs | $ 80,000 | |||||||
Clear Com Media, Inc [Member] | Minimum [Member] | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 3 years | |||||||
Clear Com Media, Inc [Member] | Maximum [Member] | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years | |||||||
Clear Com Media, Inc [Member] | Scenario, Adjustment [Member] | ||||||||
Finite-Lived Intangible Assets, Accumulated Amortization | $ 15,000 | |||||||
CEN Biotech Ukraine [Member] | ||||||||
Due from Related Parties, Total | $ 1,299,328 | $ 1,229,328 | $ 1,179,328 | |||||
Percentage of Related Party's Equity Interest Owned by Director | 51% | |||||||
CEN Biotech Ukraine [Member] | Usamakh Saadikh [Member] | ||||||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | |||||||
Ownership Percentage | 49% |
Note 3 - Acquisition of Clear C
Note 3 - Acquisition of Clear Com Media, Inc - Estimate of Assets Acquired and Liabilities Assumed (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Goodwill | $ 1,314,134 | $ 1,314,134 |
Clear Com Media, Inc [Member] | ||
Cash | 259,470 | |
Accounts receivable | 210,536 | |
Property and equipment | 97,911 | |
Other assets | 244,540 | |
Identifiable intangibles | 456,855 | |
Current financial liabilities | (344,591) | |
Other long-term liabilities | (140,078) | |
Total identifiable net assets | 784,643 | |
Goodwill | 1,335,357 | |
Net assets acquired | $ 2,120,000 |
Note 3 - Acquisition of Clear_2
Note 3 - Acquisition of Clear Com Media, Inc - Proforma Results of Operations (Details) - Clear Com Media, Inc [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | $ 1,305,985 | $ 1,242,676 |
Operating expenses | 20,437,863 | 3,720,279 |
Loss from operations | (19,131,878) | (2,477,603) |
Other income, net | 57,949 | 16,950,653 |
(Loss) income before income taxes | (19,073,929) | 14,473,050 |
Income tax expense | (61,032) | 32,892 |
Net (loss) income | $ (19,012,897) | $ 14,440,158 |
Basic (in dollars per share) | $ (0.43) | $ 0.46 |
Diluted (in dollars per share) | $ (0.43) | $ 0.39 |
Diluted (in shares) | 44,488,649 | 36,732,510 |
Note 4 - Intangible Assets (Det
Note 4 - Intangible Assets (Details Textual) - USD ($) | 1 Months Ended | 7 Months Ended | 12 Months Ended | |||||||
Oct. 07, 2021 | Apr. 03, 2019 | Sep. 12, 2016 | Mar. 31, 2018 | Sep. 30, 2018 | Dec. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2022 | Sep. 30, 2021 | Jul. 09, 2021 | |
Stock Issued During Period, Value, Purchase of Assets | $ 5 | |||||||||
Development of Acquired Technology, Annual Compensation for Specialist | $ 200,000 | |||||||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred | $ 4,380,000 | |||||||||
Contingent Consideration Classified as Equity, Fair Value Disclosure | $ 1,380,000 | $ 1,380,000 | ||||||||
Impairment of Real Estate | $ 0 | $ 0 | ||||||||
Tesla Digital Transaction [Member] | ||||||||||
Stock Issued During Period, Value, Purchase of Assets | $ 2,042,500 | |||||||||
Stock Issued During Period, Shares, Purchase of Assets (in shares) | 5,000,000 | |||||||||
Stock Issued During Period, Purchase of Assets, Expense | $ 1,634,000 | |||||||||
Asset Acquisition, Liabilities Assumed | 302,186 | |||||||||
Gain (Loss) on Settlement of Lighting Patent Purchase, Including Shares Issued | $ (1,331,814) | |||||||||
Tesla Digital [Member] | ||||||||||
Stock Issued During Period, Shares, Purchase of Assets (in shares) | 1,000,000 | |||||||||
Patented Technology [Member] | ||||||||||
Stock Issued During Period, Value, Purchase of Assets | 5,000,000 | |||||||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred | 2,161,467 | |||||||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred | $ 202,666 | |||||||||
Lighting Patent [Member] | ||||||||||
Finite-Lived Intangible Asset, Expected Amortization, Year One | $ 424,812 | |||||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eleven | $ 283,215 | |||||||||
Customers Relationships and Trade Names [Member] | ||||||||||
Finite-Lived Intangible Asset, Expected Amortization, Year One | $ 29,300 | |||||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Four | 25,400 | |||||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Five | 21,400 | |||||||||
Finite-Lived Intangible Asset, Expected Amortization, Year Seven | $ 32,100 |
Note 4 - Intangible Assets - In
Note 4 - Intangible Assets - Intangible Assets (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2022 | |
Finite-lived intangible assets, gross | $ 7,352,346 | $ 7,352,346 |
Less: Accumulated amortization | 2,280,315 | 2,379,370 |
Net | 5,072,031 | 4,972,976 |
Lighting Patent [Member] | ||
Finite-lived intangible assets, gross | $ 6,797,000 | 6,797,000 |
Finite-Lived Intangible Asset, Useful Life (Year) | 16 years | |
Technology-Based Intangible Assets [Member] | ||
Finite-lived intangible assets, gross | $ 276,080 | 276,080 |
Customer Relationships [Member] | ||
Finite-lived intangible assets, gross | $ 149,872 | 149,872 |
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years | |
Computer Software, Intangible Asset [Member] | ||
Finite-lived intangible assets, gross | $ 105,730 | 105,730 |
Trade Names [Member] | ||
Finite-lived intangible assets, gross | $ 23,664 | $ 23,664 |
Finite-Lived Intangible Asset, Useful Life (Year) | 3 years |
Note 5 - Loans Payable (Details
Note 5 - Loans Payable (Details Textual) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) shares | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) shares | Dec. 31, 2021 CAD ($) | |
Stock Issued During Period, Shares, New Issues (in shares) | shares | 33,000 | |||||||
Interest Expense, Debt, Total | $ 31,227 | $ 162,975 | $ 66,102 | $ 293,603 | ||||
Stock Issued During Period, Value, New Issues | $ 5,030 | $ 62,100 | ||||||
Canada Emergency Wage and Canada Emergency Rent Subsidies [Member] | ||||||||
Government Assistance, Amount | $ 171,078 | |||||||
CEBA, Loan Payable [Member] | ||||||||
Unsecured Long-Term Debt, Noncurrent | $ 31,552 | $ 40,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 5% | 5% | ||||||
Debt Instrument, Principal Increase if not Repaid by Specified Date | $ 15,776 | $ 20,000 | ||||||
Short-term Loan Payable to Private Investors [Member] | ||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 1,463,793 | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 677,955 | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 7% | 7% | 7% | 7% | ||||
Additional Paid-in Capital [Member] | ||||||||
Stock Issued During Period, Value, New Issues | $ 5,030 | $ 62,100 | ||||||
Individual Lenders [Member] | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 62,000 | 72,000 | ||||||
Stock Issued During Period, Shares, New Issues, Not yet Recognized (in shares) | shares | 10,000 | |||||||
Stock Issued During Period, Value, New Issues, Not yet Recognized | $ 4,012 | |||||||
Interest Expense, Debt, Total | 57,876 | $ 63,720 | ||||||
Individual Lenders [Member] | Additional Paid-in Capital [Member] | ||||||||
Stock Issued During Period, Value, New Issues | $ 53,864 | 63,720 | ||||||
Global Holdings International, LLC [Member] | ||||||||
Derecognition of Debt, Amount | 9,600,000 | |||||||
Derecognition of Debt, Accrued Interest, Amount | $ 11,579,043 |
Note 5 - Loans Payable - Loans
Note 5 - Loans Payable - Loans Payable (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | $ 1,688,793 | $ 1,688,793 |
Loan payable | 1,688,793 | 1,688,793 |
Short-term Loan Payable to Private Investors [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 871,398 | 871,398 |
Loan payable | 871,398 | 871,398 |
Short-term Loan Payable to Multiple Investors [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 592,395 | 592,395 |
Loan payable | 592,395 | 592,395 |
Second Short-term Loan Payable to an Individual [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 100,000 | 100,000 |
Loan payable | 100,000 | 100,000 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 75,000 | 75,000 |
Loan payable | 75,000 | 75,000 |
Short-term Loan Payable to an Individual [Member] | ||
Loans payable, on demand, to a private investor for the original amount of CAD 1,104,713, bearing interest at 7% per annum. | 50,000 | 50,000 |
Loan payable | $ 50,000 | $ 50,000 |
Note 5 - Loans Payable - Loan_2
Note 5 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Short-term Loan Payable to Private Investors [Member] | ||
Original Amount | $ 1,104,713 | $ 1,104,713 |
Interest Rate | 7% | 7% |
Short-term Loan Payable to Multiple Investors [Member] | ||
Interest Rate | 12% | 12% |
Maturity Date, start | Jun. 01, 2018 | Jun. 01, 2018 |
Maturity Date, end | May 31, 2021 | May 31, 2021 |
Second Short-term Loan Payable to an Individual [Member] | ||
Share Interest (in shares) | 4,000 | 4,000 |
Maturity Date | Apr. 16, 2022 | Apr. 16, 2022 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Interest Rate | 15% | 15% |
Maturity Date | Jun. 30, 2016 | Jun. 30, 2016 |
Short-term Loan Payable to an Individual [Member] | ||
Share Interest (in shares) | 2,000 | 2,000 |
Maturity Date | Jul. 16, 2021 | Jul. 16, 2021 |
Note 6 - Loans Payable- Relat_3
Note 6 - Loans Payable- Related Party (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Interest Expense, Related Party | $ 14,996 | $ 113,414 | $ 104,357 | $ 236,650 | |||
Stock Issued During Period, Shares, New Issues (in shares) | 33,000 | ||||||
Stock Issued During Period, Value, New Issues | $ 5,030 | $ 62,100 | |||||
Related Parties Lenders [Member] | |||||||
Stock Issued During Period, Shares, New Issues (in shares) | 33,000 | 96,000 | |||||
Stock Issued During Period, Value, New Issues | $ 5,030 | $ 81,302 | |||||
Loans Payable to Related Party [Member] | |||||||
Interest Payable, Related Party | 671,665 | $ 568,969 | |||||
Interest Expense, Related Party | $ 189,182 | $ 202,640 |
Note 6 - Loans Payable - Relate
Note 6 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Long-term Debt | $ 2,701,641 | $ 2,701,641 |
Mr. Chaaban [Member] | ||
Long-term Debt | 1,388,122 | 1,388,122 |
Creative Edge [Member] | ||
Long-term Debt | 601,500 | 601,500 |
R&D Labs Canada, Inc [Member] | ||
Long-term Debt | 300,000 | 300,000 |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt | 237,019 | 237,019 |
Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||
Long-term Debt | 100,000 | 100,000 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt | 75,000 | 75,000 |
Joseph Byrne [Member] | ||
Long-term Debt | $ 0 | $ 0 |
Note 6 - Loans Payable - Rela_2
Note 6 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 USD ($) shares | Dec. 31, 2021 USD ($) shares | Jun. 30, 2022 CAD ($) shares | Dec. 31, 2021 CAD ($) shares | |
Joseph Byrne [Member] | ||||
Related Party Interest | 5% | 5% | ||
Loans Payable to Related Party [Member] | Mr. Chaaban [Member] | ||||
Interest Rate | 12% | 12% | 12% | 12% |
Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 | ||
Loans Payable to Related Party [Member] | Creative Edge [Member] | ||||
Interest Rate | 10% | 10% | 10% | 10% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Loans Payable to Related Party [Member] | R&D Labs Canada, Inc [Member] | ||||
Interest Rate | 8% | 8% | 8% | 8% |
Maturity Date | Oct. 02, 2019 | Oct. 02, 2019 | ||
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | ||||
Interest Rate | 10% | 10% | 10% | 10% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Original Amount | $ 198,660 | $ 198,660 | $ 48,630 | $ 48,630 |
Loans Payable to Related Party [Member] | Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||||
Maturity Date | Apr. 16, 2022 | Apr. 16, 2022 | ||
Share Interest (in shares) | 4,000 | 4,000 | 4,000 | 4,000 |
Related Party Interest | 5% | 5% | 5% | 5% |
Loans Payable to Related Party [Member] | Director, Alex Tarrabain [Member] | ||||
Maturity Date | Apr. 16, 2022 | Apr. 16, 2022 | ||
Share Interest (in shares) | 3,000 | 3,000 | 3,000 | 3,000 |
Loans Payable to Related Party [Member] | Joseph Byrne [Member] | ||||
Share Interest (in shares) | 2,000 | 2,000 | 2,000 | 2,000 |
Related Party Interest | 5% | 5% | 5% | 5% |
Note 7 - Convertible Notes (Det
Note 7 - Convertible Notes (Details Textual) | 6 Months Ended | 12 Months Ended | |||
Aug. 14, 2022 USD ($) | Jun. 30, 2022 USD ($) shares | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) | |
Proceeds from Convertible Debt | $ 70,000 | $ 408,395 | |||
Conversion of Convertible Notes into Common Stock [Member] | |||||
Debt Conversion, Original Debt, Amount | $ 100,000 | $ 5,173,785 | |||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 416,667 | 3,488,883 | |||
Convertible Debt Payable to Non-related Party [Member] | |||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 180,098 | ||||
Convertible Debt [Member] | |||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 111,306 | $ 0 | |||
Debt Instrument, Convertible, Number of Equity Instruments | 914,732 | ||||
Proceeds from Convertible Debt | $ 70,000 | ||||
Convertible Debt [Member] | Subsequent Event [Member] | |||||
Debt Instrument, Convertible, Number of Equity Instruments | 363,767 | ||||
Debt Instrument, Debt Default, Amount | $ 576,472 |
Note 7 - Convertible Notes - Co
Note 7 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Long-term Debt, gross | $ 791,472 | $ 721,472 |
Long-term Debt, gross | 791,472 | 721,472 |
Less unamortized debt discount | 78,142 | 78,142 |
Long-term Debt | 713,330 | 643,330 |
Less current portion | 713,330 | 643,330 |
Convertible notes payable, less current portion | 0 | 0 |
Convertible Notes 1[Member] | ||
Long-term Debt, gross | 576,472 | 576,472 |
Long-term Debt, gross | 576,472 | 576,472 |
Convertible Notes 2 [Member] | ||
Long-term Debt, gross | 145,000 | 145,000 |
Long-term Debt, gross | 145,000 | 145,000 |
Convertible Notes 3 [Member] | ||
Long-term Debt, gross | 0 | 0 |
Long-term Debt, gross | 0 | 0 |
Convertible Notes 4 [Member] | ||
Long-term Debt, gross | 70,000 | 0 |
Long-term Debt, gross | $ 70,000 | $ 0 |
Note 7 - Convertible Notes - _2
Note 7 - Convertible Notes - Convertible Notes (Details) (Parentheticals) - Convertible Debt [Member] | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | Jun. 30, 2022 CAD ($) | Dec. 31, 2021 CAD ($) | |
Conversion Rights | 914,732 | |||
Convertible Notes 1[Member] | ||||
Interest Rate | 5% | 5% | 5% | 5% |
Conversion Rights | 363,767 | 363,767 | ||
Maturity Date, start | May 01, 2018 | May 01, 2018 | ||
Maturity Date, end | Oct. 31, 2021 | Oct. 31, 2021 | ||
Convertible Notes 2 [Member] | ||||
Interest Rate | 5% | 5% | 5% | 5% |
Conversion Rights | 550,965 | 550,965 | ||
Maturity Date, start | Jun. 01, 2022 | Jun. 01, 2022 | ||
Maturity Date, end | Dec. 31, 2022 | Dec. 31, 2022 | ||
Convertible Notes 3 [Member] | ||||
Interest Rate | 7% | 7% | 7% | 7% |
Conversion Rights | 335,833 | 335,833 | ||
Original Amount | $ 1,104,713 | $ 1,104,713 | ||
Convertible Notes 4 [Member] | ||||
Interest Rate | 8% | 8% | 8% | 8% |
Original Amount | $ 70,000 | $ 70,000 | ||
Discount rate | 35% | 35% | ||
Variable conversion price | 65% | 65% |
Note 8 - Convertible Notes - _3
Note 8 - Convertible Notes - Related Party (Details Textual) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Aug. 14, 2022 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Interest Expense, Related Party | $ 14,996 | $ 113,414 | $ 104,357 | $ 236,650 | |||
Convertible Debt Payable to Related Party [Member] | |||||||
Interest Payable, Related Party | 1,977,812 | 1,977,812 | $ 1,201,790 | ||||
Interest Expense, Related Party | 104,357 | 229,318 | |||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 18,141 | $ 0 | |||||
Long-term Debt, Total | $ 162,639 | $ 162,639 | $ 162,639 | ||||
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 76,123 | 76,123 | |||||
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 170,611 | ||||||
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Subsequent Event [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 76,123 | ||||||
Debt Instrument, Debt Default, Amount | $ 121,796 | ||||||
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Joseph Byrne [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 63,997 | ||||||
Long-term Debt, Total | $ 102,395 |
Note 8 - Convertible Notes Paya
Note 8 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Long-term Debt, gross | $ 169,796 | $ 169,796 |
Less unamortized debt discount | 7,157 | 7,157 |
Long-term Debt | 162,639 | 162,639 |
Joseph Byrne [Member] | ||
Long-term Debt, gross | 121,796 | 121,796 |
Jeff Thomas [Member] | ||
Long-term Debt, gross | $ 48,000 | $ 48,000 |
Note 8 - Convertible Notes Pa_2
Note 8 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) - Convertible Debt Payable to Related Party [Member] | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Joseph Byrne [Member] | ||
Interest Rate | 12% | 12% |
Conversion Rights | 76,123 | 76,123 |
Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 |
Jeff Thomas [Member] | ||
Interest Rate | 5% | 5% |
Conversion Rights | 94,488 | 94,488 |
Maturity Date | May 24, 2022 | May 24, 2022 |
Note 9 - Income Taxes (Details
Note 9 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2022 | |
Operating Loss Carryforwards | $ 46,569,501 | ||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 4,900,000 | $ 3,400,000 |
Note 9 - income Taxes - Schedul
Note 9 - income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Deferred tax asset - net operating losses | $ 8,300,000 | $ 3,400,000 |
Deferred tax asset valuation allowance | (8,300,000) | (3,400,000) |
Net deferred tax asset | $ 0 | 0 |
Deferred tax assets | ||
SR&ED credits | 39,464 | |
Deferred tax liabilities | ||
Property and equipment | (11,357) | |
Intangible assets, including goodwill | (25,387) | |
Total deferred tax liabilities | (36,744) | |
Net deferred tax asset | $ 2,720 |
Note 9 - Income Taxes - The Tax
Note 9 - Income Taxes - The Tax Benefit for CCM Income Taxes (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Current | $ (33,621) | |
Deferred | (2,735) | |
Net income tax benefit | $ (36,356) | $ 0 |
Note 9 - Income Taxes - Reconci
Note 9 - Income Taxes - Reconciliation of Effective Tax Rate (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income tax (benefit) expense at statutory rate of 26.5% | $ (5,019,103) | $ 3,776,156 |
Valuation allowance | 5,020,280 | (3,776,156) |
SR&ED credits | (19,198) | 0 |
Other | (18,335) | 0 |
Income tax benefit | (36,356) | 0 |
Growth [Member] | ||
Income tax (benefit) expense at statutory rate of 26.5% | (5,020,280) | 3,776,156 |
Valuation allowance | 5,020,280 | (3,776,156) |
SR&ED credits | 0 | 0 |
Other | 0 | 0 |
Income tax benefit | 0 | 0 |
Digital [Member] | ||
Income tax (benefit) expense at statutory rate of 26.5% | 1,177 | 0 |
Valuation allowance | 0 | 0 |
SR&ED credits | (19,198) | 0 |
Other | (18,335) | 0 |
Income tax benefit | $ (36,356) | $ 0 |
Note 9 - Income Taxes - Recon_2
Note 9 - Income Taxes - Reconciliation of Effective Tax Rate (Details) (Parentheticals) | 12 Months Ended |
Dec. 31, 2020 | |
income tax | 26.50% |
Note 10 - Shareholders' Defic_2
Note 10 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | |
Common Stock, No Par Value (in dollars per share) | $ 0 | $ 0 | $ 0 |
Stock Issued During Period, Shares, Employment Settlement Agreement (in shares) | 5,350,444 | ||
Stock Issued During Period, Shares, New Issues (in shares) | 33,000 | ||
Common Stock, Earned (in shares) | 10,000 | ||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,085,343 |
Note 11 - Related Party Trans_3
Note 11 - Related Party Transactions (Details Textual) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||
Sep. 01, 2022 CAD ($) | Aug. 01, 2020 USD ($) shares | Oct. 01, 2017 CAD ($) | Jan. 31, 2017 CAD ($) | Mar. 31, 2022 CAD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2017 USD ($) | Jun. 30, 2022 USD ($) | Dec. 14, 2017 | Dec. 02, 2017 | |
Notes Receivable, Related Parties, Current | $ 0 | $ 0 | |||||||||
Accounts Payable, Related Parties, Current | 101,422 | 75,561 | |||||||||
Operating Lease, Liability, Total | 310,671 | $ 164,997 | |||||||||
Operating Lease, Expense | $ 46,000 | 35,000 | |||||||||
Operating Lease, Weighted Average Discount Rate, Percent | 6.76% | ||||||||||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 4 years 4 months 24 days | ||||||||||
Operating Lease, Right-of-Use Asset | $ 138,103 | 111,853 | |||||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | |||||||||||
Operating Lease, Monthly Rent | $ 2,608 | ||||||||||
Operating Lease, Impairment Loss | $ 146,795 | ||||||||||
Operating Lease, Liability, Total | 177,686 | 164,997 | |||||||||
Operating Lease, Expense | $ 13,000 | 35,000 | |||||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member] | |||||||||||
Operating Lease, Monthly Rent | $ 3,390 | ||||||||||
Lease Arrangement, 20 North Rear Road [Member] | |||||||||||
Operating Lease, Monthly Rent | $ 4,000 | ||||||||||
Operating Lease, Liability, Total | $ 45,118 | ||||||||||
Lessee, Operating Lease, Term of Contract (Year) | 5 years | ||||||||||
Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares) | shares | 36,500 | ||||||||||
Stock Issued During Period, Value, Issued for Settlement of Lease Termination | $ 50,700 | ||||||||||
Operating Lease, Right-of-Use Asset | $ 48,110 | ||||||||||
Lessee, Operating Lease, Discount Rate | 8% | ||||||||||
Gain (Loss) on Termination of Lease | $ 53,692 | ||||||||||
Lease Arrangement, 20 North Rear Road [Member] | General and Administrative Expense [Member] | |||||||||||
Operating Lease, Expense | $ 20,000 | ||||||||||
Minimum [Member] | |||||||||||
Operating Lease, Monthly Rent | $ 844 | ||||||||||
Maximum [Member] | |||||||||||
Operating Lease, Monthly Rent | $ 5,595 | ||||||||||
CEN Biotech Ukraine [Member] | XN Pharma [Member] | |||||||||||
Ownership Percentage | 49% | ||||||||||
CEN Biotech Ukraine [Member] | |||||||||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | ||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 51% | ||||||||||
Emergence Global [Member] | |||||||||||
Notes Receivable, Related Parties, Current | 17,901 | ||||||||||
Joseph Byrne [Member] | |||||||||||
Percentage of Related Party's Equity Interest Owned | 5% | ||||||||||
CEN Biotech Ukraine [Member] | |||||||||||
Due from Related Parties, Total | $ 1,299,328 | 1,179,328 | $ 1,229,328 | ||||||||
Percentage of Related Party's Equity Interest Owned by Director | 51% | ||||||||||
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member] | |||||||||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | $ 255,141 | ||||||||||
Notes Receivable, Related Parties | 44,859 | ||||||||||
Board Members and Officers [Member] | Consulting Fees [Member] | |||||||||||
Related Party Transaction, Amounts of Transaction | 188,718 | 124,800 | |||||||||
Due to Related Parties, Total | 518,918 | $ 330,200 | |||||||||
Chief Technology Officer [Member] | Payoll Expenses [Member] | |||||||||||
Related Party, General and Administrative Expenses | 94,553 | ||||||||||
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member] | |||||||||||
Notes Payable, Related Parties | $ 300,000 | ||||||||||
Director, Joe Byrne [Member] | Advances Made to the Company [Member] | |||||||||||
Accounts Payable, Related Parties, Current | 8,347 | ||||||||||
The Chief Financial Officer, Alex Tarrabain [Member] | |||||||||||
Accounting Advisory Services, Fees | 13,320 | ||||||||||
The Chief Financial Officer, Alex Tarrabain [Member] | Reimbursable Expenses [Member] | |||||||||||
Accounts Payable, Related Parties, Current | 30,795 | ||||||||||
The Chief Technology Officer, Lawrence Lehoux [Member] | Reimbursable Expenses [Member] | |||||||||||
Accounts Payable, Related Parties, Current | $ 48,960 |
Note 11 - Related Party Trans_4
Note 11 - Related Party Transactions - Future Minimum Operating Lease Payments (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
2022 | $ 119,543 | |
2023 | 90,325 | |
2024 | 61,897 | |
2025 | 32,088 | |
2026 | 32,088 | |
Thereafter | 24,066 | |
Total lease payments | 360,007 | |
Less imputed interest | 49,336 | |
Present value of lease liability | $ 310,671 | $ 164,997 |
Note 12 - Stock Based Compens_3
Note 12 - Stock Based Compensation (Details Textual) - USD ($) | 3 Months Ended | 11 Months Ended | 12 Months Ended | ||||||||||||
Apr. 19, 2022 | Dec. 06, 2021 | Jul. 13, 2021 | Jun. 25, 2021 | Apr. 02, 2021 | Aug. 27, 2020 | Apr. 17, 2020 | Apr. 02, 2020 | May 16, 2019 | Nov. 30, 2017 | Jun. 25, 2021 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Nov. 29, 2017 | |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,085,343 | 1,085,343 | |||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 500,000 | 162,500 | 225,000 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 162,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ 16,562,822 | $ 1,237,250 | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ 738,250 | $ 738,250 | |||||||||||||
President [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 8,750,000 | ||||||||||||||
President [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 7,400,000 | ||||||||||||||
Chief Executive Officer [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | ||||||||||||||
Accrued Salaries | $ 58,500 | ||||||||||||||
Number of Restricted Shares to settle Accrued Salaries (in shares) | 337,500 | ||||||||||||||
Chief Executive Officer [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 325,000 | ||||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,500,000 | ||||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,140,000 | ||||||||||||||
Vice President [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 750,000 | ||||||||||||||
Vice President [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 300,000 | ||||||||||||||
Chief Financial Officer [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | ||||||||||||||
Chief Financial Officer [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 350,000 | ||||||||||||||
Senior Vice President of Deals and Acquisitions [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 2,500,000 | ||||||||||||||
Senior Vice President of Deals and Acquisitions [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 700,000 | ||||||||||||||
Director, Harold Aubrey de Lavenu [Member] | |||||||||||||||
Annual Salary | $ 31,200 | ||||||||||||||
Former Chief Executive Officer, President and Chairman of the Board of Directors [Member] | |||||||||||||||
Accrued Salaries | $ 133,882.19 | ||||||||||||||
Former Chief Financial Officer and Director [Member] | |||||||||||||||
Accrued Salaries | 89,682.19 | ||||||||||||||
Former Senior Vice President of Deals and Acquisitions and Director [Member] | |||||||||||||||
Accrued Salaries | 11,286.19 | ||||||||||||||
Former Vice President and Director [Member] | |||||||||||||||
Accrued Salaries | 32,482.19 | ||||||||||||||
Former Senior Executive Vice President and Director [Member] | |||||||||||||||
Accrued Salaries | $ 133,882.19 | ||||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,870,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 1,330,000 | ||||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 550,000 | ||||||||||||||
Restricted Stock [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 15,059,291 | 15,059,291 | 387,500 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 13,559,291 | 13,559,291 | 1,987,500 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value | $ 275,000 | $ 117,000 | $ 16,871,822 | $ 279,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value | $ 29,885,063 | $ 13,013,241 | |||||||||||||
Restricted Stock [Member] | CONFIEN SAS [Member] | |||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 650,000 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 897,000 | ||||||||||||||
Restricted Stock [Member] | Senior Vice President of Deals and Acquisitions [Member] | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 238,000 | ||||||||||||||
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,041,250 | ||||||||||||||
Restricted Stock [Member] | Director, Ameen Ferris [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||||
Restricted Stock [Member] | Directors Ameen Ferris and Harold Aubrey De Lavenu [Member] | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 2,816,925 | ||||||||||||||
Restricted Stock [Member] | Richard Boswell [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 2,185,679 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 3,016,237 | ||||||||||||||
Restricted Stock [Member] | Bahige Chaaban [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 3,106,122 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 4,286,435 | ||||||||||||||
Restricted Stock [Member] | Brian Payne [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,435,000 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,980,300 | ||||||||||||||
Restricted Stock [Member] | Usamakh Saadikh [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,380,000 | ||||||||||||||
Restricted Stock [Member] | Donald Strilchuck [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 341,250 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 470,925 | ||||||||||||||
Restricted Stock [Member] | Director, Alex Tarrabain [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | 300,000 | |||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 899,000 | ||||||||||||||
Restricted Stock [Member] | Former Chief Executive Officer, President and Chairman of the Board of Directors [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,785,096 | ||||||||||||||
Restricted Stock [Member] | Former Chief Financial Officer and Director [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,196,673 | ||||||||||||||
Restricted Stock [Member] | Former Senior Vice President of Deals and Acquisitions and Director [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 150,483 | ||||||||||||||
Restricted Stock [Member] | Former Vice President and Director [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 433,096 | ||||||||||||||
Restricted Stock [Member] | Former Senior Executive Vice President and Director [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,785,096 | ||||||||||||||
2017 Equity Compensation Plan [Member] | |||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 | ||||||||||||||
The 2021 Equity Compensation Plan [Member] | |||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 |
Note 12 - Stock Based Compens_4
Note 12 - Stock Based Compensation - Compensation Expenses (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Stock Based Compensation [Member] | ||
Compensation expense | $ 0 | $ 15,390,822 |
Professional Fees [Member] | ||
Compensation expense | 0 | 1,172,000 |
Stock Based Compensation and Professional Fees [Member] | ||
Compensation expense | $ 0 | $ 16,562,822 |
Note 12 - Stock Based Compens_5
Note 12 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares | 11 Months Ended | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Non-vested, number of share (in shares) | 425,000 | |||
Non-vested, weighted average grant date fair value (in dollars per share) | $ 1.01 | |||
Non-vested, weighted average remaining contractual term (Year) | 2 years 10 months 2 days | 1 year 6 months | ||
Granted, number of share (in shares) | 15,059,291 | 15,059,291 | 387,500 | |
Granted, weighted average grant date fair value (in dollars per share) | $ 1.12 | |||
Vested, number of share (in shares) | (13,559,291) | (13,559,291) | (1,987,500) | |
Vested, weighted average grant date fair value (in dollars per share) | $ 1.22 | |||
Forfeited, number of share (in shares) | 0 | |||
Forfeited, weighted average grant date fair value (in dollars per share) | $ 0 | |||
Non-vested, number of share (in shares) | 1,925,000 | 1,925,000 | ||
Non-vested, weighted average grant date fair value (in dollars per share) | $ 0.38 | $ 0.38 |
Note 13 - Net (Loss) Income Per
Note 13 - Net (Loss) Income Per Share - Antidilutive Securities (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Convertible Debt Securities [Member] | ||
Antidilutive Securities (in shares) | 1,085,343 | 0 |
Tesla Agreement Securities [Member] | ||
Antidilutive Securities (in shares) | 0 | 1,000,000 |
Note 13 - Net Income (Loss) Per
Note 13 - Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income available to common stockholders | $ 607,152 | |||||
Shares, Basic (in shares) | 61,341,187 | 27,207,044 | 61,341,187 | 27,091,577 | 61,341,187 | |
Per share, Basic (in dollars per share) | $ 0 | $ (0.06) | $ 0 | $ (0.11) | $ 0 | |
Effect of Dilutive Securities, Convertible debt | 0 | |||||
Shares, Convertible debt (in shares) | 0 | |||||
Income available to common stockholders with assumed conversions | $ 607,152 | |||||
Shares, Diluted (in shares) | 61,341,187 | |||||
Per share, Diluted (in dollars per share) | $ 0 |
Note 15 - Fair Value Disclosu_3
Note 15 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($) | Jun. 30, 2022 | Dec. 31, 2020 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 66,046 | $ 193,198 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 1,688,793 | 1,688,793 |
Loans payable – related parties | 2,701,641 | 2,701,641 |
Convertible notes payable | 713,330 | 643,330 |
Convertible notes payable – related parties | 162,639 | 162,639 |
Reported Value Measurement [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 47,400 | 31,552 |
Reported Value Measurement [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 1,299,328 | 1,299,328 |
Estimate of Fair Value Measurement [Member] | ||
Cash and cash equivalents | 66,046 | 193,198 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 1,688,793 | 1,688,793 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 713,330 | 1,890,736 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 47,400 | 31,552 |
Estimate of Fair Value Measurement [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 1,299,328 | 1,299,328 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 0 | 0 |
Loans payable | 0 | 0 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 0 | 0 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 66,046 | 193,198 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 0 | 0 |
Loans payable | 0 | 0 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 0 | 0 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 1,688,793 | 1,688,793 |
Loans payable – related parties | 0 | 0 |
Convertible notes payable | 713,330 | 1,890,736 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEBA, Loan Payable [Member] | ||
Loans payable | 47,400 | 31,552 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | $ 1,299,328 | $ 1,299,328 |
Note 16 - Subsequent Events (De
Note 16 - Subsequent Events (Details Textual) | 6 Months Ended | ||
May 24, 2022 CAD ($) shares | Jun. 30, 2022 shares | May 24, 2022 $ / shares | |
Stock Issued During Period, Shares, New Issues (in shares) | 33,000 | ||
Patents [Member] | Emergence Global Enterprises Inc. [Member] | |||
Noncash or Part Noncash Acquisition, Intangible Assets Acquired | $ | $ 7,440,000 | ||
Stock Issued During Period, Shares, New Issues (in shares) | 62,000,000 | ||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.12 | ||
Percentage of Capital Stock | 44.17% |